Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study

Translational Psychiatry, Год журнала: 2022, Номер 12(1)

Опубликована: Март 3, 2022

Abstract The acid sphingomyelinase (ASM)/ceramide system may provide a useful framework for better understanding SARS-CoV-2 infection and the repurposing of psychotropic medications functionally inhibiting sphingomyelinase/ceramide (named FIASMA medications) against COVID-19. We examined potential usefulness in patients with psychiatric disorders hospitalized severe COVID-19, an observational multicenter study conducted at Greater Paris University hospitals. Of 545 adult inpatients, 164 (30.1%) received medication upon hospital admission compared composite endpoint intubation or death between who baseline those did not time-to-event analyses adjusted sociodemographic characteristics, other medical comorbidity, medications. use was significantly associated reduced risk both crude (HR = 0.42; 95%CI 0.31–0.57; p < 0.01) primary inverse probability weighting (IPW) 0.50; 0.37–0.67; analyses. This association specific to one class medication. Patients taking antidepressant had non-FIASMA 0.57; 0.38–0.86; IPW 0.37–0.87; These associations remained significant multiple sensitivity Our results show importance ASM/ceramide COVID-19 support continuation these need large- scale clinical trials evaluating medications, particularly antidepressants,

Язык: Английский

---

The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis

PLoS ONE, Год журнала: 2022, Номер 17(10), С. e0267423 - e0267423

Опубликована: Окт. 6, 2022

Introduction Clinical Depression and the subsequent low immunity is a comorbidity that can act as risk factor for severity of COVID-19 cases. Antidepressants such Selective serotonin reuptake inhibitor Serotonin-norepinephrine inhibitors are associated with immune-modulatory effects, which dismiss inflammatory responses reduce lung tissue damage. The current systematic review meta-analysis aims to evaluate effect antidepressant drugs on prognosis in hospitalized patients. Methods A search was carried out PubMed/Medline, EMBASE, Scopus up June 14, 2022. following keywords were used: "COVID-19", "SARS-CoV-2", "2019-nCoV", "SSRI", "SNRI", “TCA”, “MAOI”, “Antidepressant”. fixed or random-effect model assessed pooled ratio (RR) 95% CI. We considered P < 0.05 statistically significant publication bias. Data analyzed by Comprehensive Meta-Analysis software, Version 2.0 (Biostat, Englewood, NJ). Results Fourteen studies included our review. Five them experimental 2350, nine observational 290,950 participants. Eight fourteen articles revealed antidepressants reducing COVID-19. drugs, including Fluvoxamine, Escitalopram, Fluoxetine, Paroxetine, among medications Venlafaxine, reasonably reduced intubation death. showed no effect, only one high bias article negative Covid-19. clinical trials fluvoxamine could significantly decrease outcomes (RR: 0.763; CI: 0.602–0.966, I2: 0.0) Findings Most evidence supports use medications, mainly may improve outcome patients SARS-CoV-2. Some contradictory findings regarding effects Further should be conducted clarify

Язык: Английский

---

Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19

Journal of Clinical Medicine, Год журнала: 2022, Номер 11(19), С. 5882 - 5882

Опубликована: Окт. 5, 2022

To reduce Coronavirus Disease 2019 (COVID-19)-related mortality and morbidity, widely available oral COVID-19 treatments are urgently needed. Certain antidepressants, such as fluvoxamine or fluoxetine, may be beneficial against COVID-19. We included 388,945 adult inpatients who tested positive for SARS-CoV-2 at 36 AP−HP (Assistance Publique−Hôpitaux de Paris) hospitals from 2 May 2020 to November 2021. compared the prevalence of antidepressant use admission in a 1:1 ratio matched analytic sample with without (N = 82,586), assessed its association 28-day all-cause 1482). Antidepressant was significantly less prevalent than control group (1.9% versus 4.8%; Odds Ratio (OR) 0.38; 95%CI 0.35−0.41, p < 0.001). associated reduced among (12.8% 21.2%; OR 0.55; 0.41−0.72, 0.001), particularly daily doses least 40 mg fluoxetine equivalents. Antidepressants high FIASMA (Functional Inhibitors Acid Sphingomyelinase) activity seem drive both associations. These infections COVID-19-related inpatients, appropriate prophylaxis and/or therapy outpatients inpatients.

Язык: Английский

---

Acute and long-term effects of COVID-19 on brain and mental health: A narrative review

Brain Behavior and Immunity, Год журнала: 2024, Номер 123, С. 928 - 945

Опубликована: Ноя. 3, 2024

Язык: Английский

---

Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2

Translational Psychiatry, Год журнала: 2022, Номер 12(1)

Опубликована: Авг. 22, 2022

Antidepressants have previously been associated with better outcomes in patients hospitalized COVID-19, but their effect on clinical deterioration among ambulatory has not fully explored. The objective of this study was to assess whether antidepressant exposure reduced emergency department (ED) or hospital visits SARS-CoV-2 infection. This retrospective cohort included adult (N = 25 034) a positive test performed non-hospital setting. Logistic regression analyses tested associations between home use medications and composite outcome ED visitation admission within 30 days. Secondary exposures individual antidepressants functional inhibition acid sphingomyelinase (FIASMA) activity. Patients were less likely experience the primary compared without (adjusted odds ratio [aOR] 0.89, 95% CI 0.79-0.99, p 0.04). association only observed daily doses at least 20 mg fluoxetine-equivalent (aOR 0.87, 0.77-0.99, 0.04), lower than 0.94, 0.80-1.11, 0.48). In exploratory secondary analyses, incidence also selective serotonin reuptake inhibitors 0.75-0.99, bupropion 0.70, 0.55-0.90, 0.005), FIASMA drugs 0.03). Antidepressant patients, dose-dependent manner. These data support model antidepressants' effects against COVID-19.

Язык: Английский

---

Association between serum lithium level and incidence of COVID-19 infection

The British Journal of Psychiatry, Год журнала: 2022, Номер 221(1), С. 425 - 427

Опубликована: Март 23, 2022

Summary An antiviral effect of lithium has been proposed, but never investigated for coronavirus disease 2019 (COVID-19). Using electronic health records 26 554 patients with documented serum levels during the pandemic, we show that 6-month COVID-19 infection incidence was lower among matched ‘therapeutic’ (0.50–1.00) versus ‘subtherapeutic’ (0.05–0.50) (hazard ratio (HR) = 0.82, 95% CI 0.69–0.97, P 0.017) and using valproate (HR 0.79, 0.67–0.92, 0.0023). Lower rates were observed both new diagnoses positive polymerase chain reaction tests, regardless underlying psychiatric diagnosis vaccination status.

Язык: Английский

---

COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review

Journal of Clinical Psychopharmacology, Год журнала: 2022, Номер 42(3), С. 284 - 292

Опубликована: Апрель 14, 2022

Studies for repurposed drugs in severe acute respiratory syndrome coronavirus type 2-infected and disease 2019 (COVID-19) patients are ongoing. According to preclinical research, antidepressants (ADs) might be useful the treatment of COVID-19.

Язык: Английский

---

Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(21), С. 13623 - 13623

Опубликована: Ноя. 7, 2022

The coronavirus disease 2019 (COVID-19) pandemic continues to cause significant morbidity and mortality worldwide. Since a large portion of the world's population is currently unvaccinated or incompletely vaccinated has limited access approved treatments against COVID-19, there an urgent need continue research on treatment options, especially those at low cost which are immediately available patients, particularly in low- middle-income countries. Prior vitro observational studies have shown that fluoxetine, possibly through its inhibitory effect acid sphingomyelinase/ceramide system, could be promising antiviral anti-inflammatory COVID-19. In this report, we evaluated potential activities fluoxetine K18-hACE2 mouse model SARS-CoV-2 infection, variants concern vitro, i.e., ancestral strain, Alpha B.1.1.7, Gamma P1, Delta B1.617 Omicron BA.5. Fluoxetine, administrated after significantly reduced lung tissue viral titres expression several inflammatory markers (i.e., IL-6, TNFα, CCL2 CXCL10). It also inhibited replication all vitro. A modulation ceramide system tissues, as reflected by increase ratio HexCer 16:0/Cer 16:0 fluoxetine-treated mice, may contribute explain these effects. Our findings demonstrate properties activity concern, establishing very candidate for prevention infection pathogenesis.

Язык: Английский

---

Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study

Molecular Psychiatry, Год журнала: 2023, Номер 28(12), С. 5411 - 5418

Опубликована: Март 3, 2023

Abstract Prior research suggests that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) used for the treatment of obsessive-compulsive disorder and major depressive disorder, could be repurposed against COVID-19. We undertook prospective interventional open-label cohort study to evaluate efficacy tolerability fluvoxamine among inpatients with laboratory-confirmed COVID-19 in Uganda. The main outcome was all-cause mortality. Secondary outcomes were hospital discharge complete symptom resolution. included 316 patients, whom 94 received addition standard care [median age, 60 years (IQR = 37.0); women, 52.2%]. Fluvoxamine use significantly associated reduced mortality [AHR 0.32; 95% CI 0.19–0.53; p < 0.001, NNT 4.46] increased resolution [AOR 2.56; 1.53–5.51; 4.44]. Sensitivity analyses yielded similar results. These effects did not differ by clinical characteristic, including vaccination status. Among 161 survivors, time 0.81, (0.54–1.23), 0.32]. There trend toward greater side (7.45% versus 3.15%; SMD 0.21; χ 2 3.46, 0.06), most which light or mild severity none serious. One hundred mg prescribed twice daily 10 days well tolerated resolution, without significant increase discharge, Large-scale randomized trials are urgently needed confirm these findings, especially low- middle-income countries, where access vaccines approved treatments is limited.

Язык: Английский

---

Psychotropic drug repurposing for COVID-19: A Systematic Review and Meta-Analysis

European Neuropsychopharmacology, Год журнала: 2022, Номер 66, С. 30 - 44

Опубликована: Окт. 20, 2022

Several psychotropic drugs, including antidepressants (AD), mood stabilizers, and antipsychotics (AP) have been suggested to favorable effects in the treatment of COVID-19. The aim this systematic review meta-analysis was collect evidence from studies concerning scientific for repurposing drugs COVID-19 treatment. Two independent authors searched PubMed-MEDLINE, Scopus, PsycINFO, ClinicalTrials.gov databases, reviewed reference lists articles eligible published up 13th December 2021. All computational, preclinical clinical (observational and/or RCTs) on effect any drug Sars-CoV-2 or patients with were considered inclusion. We conducted random meta-analyses reporting AD AP outcomes. 29 included synthesis: 15 clinical, 9 preclinical, 5 computational studies. could be quantitative analyses. did not increase risk severe (RR= 1.71; CI 0.65-4.51) mortality (RR=0.94; 0.81-1.09). Fluvoxamine associated a reduced (OR=0.15; 0.02-0.95). increased (RR=3.66; 2.76-4.85) (OR=1.53; 1.15-2.03). might possible candidate due its anti-inflammatory antiviral potential, while other is still controversial. Although are worse outcomes, their use should evaluated case ongoing discontinued psychiatric patients.

Язык: Английский

---